“The scientific team at Disarm discovered an important and highly promising approach to combat axonal degeneration. We will move quickly to develop their SARM1 inhibitors into potential medicines for peripheral neuropathy and neurological diseases, such as ALS and multiple sclerosis,” Mark Mintun, MD, vice president of pain and neurodegeneration research at Lilly, said in a press release.
- Welcome to the MND Association Forum.
If this is your first visit, be sure to check out the Forum Guidelines. You will need to Register before you can post. All registrations are manually approved by the Forum Admin team to try and help prevent spam so there may be a slight delay between registering and being able to post.
To start viewing posts, select the section of the forum that you want to visit from the selection below.
Comment